Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

سلطنة عُمان
وزارة الصحة
مركز سلامة الدواء
مسقط

To:
SO/1, Pharmacy Department, the Medical City for Military and Security Services
Director of Pharmaceutical Care, Royal Hospital
Director of Pharmaceutical Care, Khoula Hospital
Pharmacist Incharge, Al Nahda Hospital
Director of Pharmaceutical Care, DGHS, Muscat Governorate
Director of Pharmaceutical Care, DGHS, Al Dakhliya Governroate
Director of Pharmaceutical Care, DGHS, South Batinah Governorate
Director of Pharmaceutical Care, DGHS, North Batinah Governorate
Director of Pharmaceutical Care, DGHS, Al Dhahira Governorate
Director of Pharmaceutical Care, DGHS, North Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, South Sharqiya Governorate
Director of Pharmaceutical Care, DGHS, Musandam Governorate
Director of Pharmaceutical Care, DGHS, Dhofar Governorate
Director of Pharmaceutical Care, DGHS, Al Wusta Governorate
Director of Pharmaceutical Care, DGHS, Buraimi Governorate
Director of Pharmaceutical Care, DGMS
Pharmacist Incharge, Al Massarah Hospital
HOD, Pharmacy Department, Sultan Qaboos University Hospital
Pharmacist Incharge, The Sultan's Special Force
Pharmacist Incharge, Petroleum Development of Oman
Pharmacist Incharge, LNG Oman

After Compliments,

Please find attached our Circular No 165/2025 dated 3/July/2025 regarding Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Associated with Semaglutide.

Copy to:

- Director General, DSC
- Director of Drug Control Department, DSC
- Director of Pharmaceutical Licensing Department, DSC
- Director of Central Quality Control Lab., DSC
- Director Medical Device Control, DSC
- Supdt. of Central Drug Information
- Head of Cordn. & FU

DSC
مركز سلامة الدواء
Drug Safety Center

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om

Sultanate of Oman
Ministry of Health
Drug Safety Center
Muscat

Circular No. 165 / 2025

09-01-1447 H
03-07-2025

سلطنة عُمان
وزارة الصحة
مركز سلامة الدواء
مسقط

نتقدم بثقة
Moving Forward with Confidence
رؤية عُمان 2040

Drug Safety Update

Subject: Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Associated with Semaglutide.

The Drug Safety Center (DSC) would like to inform you that the World Health Organization (WHO) has issued a safety alert to inform healthcare professionals and regulatory authorities on the risk of non-arteritis anterior ischemic optic neuropathy (NAION) associated with the use of Semaglutide-containing medicines. The European Medicines Agency (EMA) has recommended updating the medicine information for this medicine to include NAION as a side effect, classified as very rare in frequency.

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is the active ingredient in medications used to treat type 2 diabetes and obesity.

NAION is a leading cause of vision loss in adults and the second most common optic neuropathy after glaucoma. It typically presents as sudden, painless, monocular vision loss accompanied by optic disc edema. The vision loss is generally irreversible, and there is currently no effective treatment available

Following a review of clinical trial data, post-marketing surveillance, and published medical literature, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that NAION should be listed as a very rare adverse event, occurring in approximately 1 in 10,000 users.

If patients experience a sudden loss of vision or rapidly worsening eyesight during treatment with semaglutide, they should contact their doctor without delay. If NAION is confirmed, treatment with semaglutide should be stopped.

Call to report:

Semaglutide is registered in Oman, healthcare professionals, patients, and caregivers are requested to submit adverse drug reaction reports to the pharmacovigilance & Drug Information department in the DSC.

PH. IBRAHIM NASSER AL RASHDI
DIRECTOR GENERAL

DRUG SAFETY CENTER
SULTANATE OF OMAN - MINISTRY OF HEALTH

DSC
مركز سلامة الدواء
Drug Safety Center

ص.ب: ٣٩٣ مسقط - الرمز البريدي: ١٠٠ - هاتف: ٢٢٣٥٧١١١ - فاكس: ٢٢٣٥٨٤٨٩
P.O. Box: 393 Muscat - Postal Code: 100 - Tel: 22357111 - Fax: 22358489
@DSCPHO Email: dscpho@moh.gov.om